Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unique MAP Kinase binding sites.

Radha Akella1, Thomas M Moon, Elizabeth J Goldsmith

  • 1Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8816, USA.

Biochimica Et Biophysica Acta
|December 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural Basis for Potassium Inhibition of WNK Kinases.

Biochemistry·2026
Same author

Engineered ipilimumab variants that bind human and mouse CTLA-4.

mAbs·2025
Same author

Water and chloride as allosteric inhibitors in WNK kinase osmosensing.

eLife·2024
Same author

Water and chloride as allosteric inhibitors in WNK kinase osmosensing.

bioRxiv : the preprint server for biology·2023
Same author

Hydrostatic Pressure Sensing by WNK kinases.

Molecular biology of the cell·2023
Same author

Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening.

Drug design, development and therapy·2023
Same journal

Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Molecular Basis of Disease Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

General Subjects Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Erratum to 'on the role of exchangeable hydrogen bonds for the kinetics of P680<sup>+·</sup> Q<sub>A</sub> <sup>-·</sup> formation and P680<sup>+·</sup> Pheo<sup>-·</sup> recombination in photosystem II' [Biochim. Biophys. Acta 1276 (1996) 35-44].

Biochimica et biophysica acta·2019
Same journal

Oligomeric state of the light-harvesting complexes B800-850 and B875 from purple bacterium Rubrivivax gelatinosus in detergent solution.

Biochimica et biophysica acta·2019
Same journal

Regulation of pigment content and enzyme activity in the cyanobacterium Nostoc sp. Mac grown in continuous light, a light-dark photoperiod, or darkness.

Biochimica et biophysica acta·2019
See all related articles

Map kinases are crucial drug targets. New research reveals unique binding sites on MAP kinases, beyond the ATP site, offering novel strategies for developing targeted therapies for cancer and autoimmune diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Mitogen-activated protein (MAP) kinases are key targets for treating autoimmune diseases, cancer, and apoptosis-related conditions.
  • Current drug discovery focuses on inhibiting MAP kinases at the ATP-binding site or the DFG-out site, similar to other protein kinase inhibitors.

Purpose of the Study:

  • To explore novel inhibition sites on MAP kinases distinct from the ATP-binding site.
  • To present crystallographic evidence for unique substrate and small molecule binding sites within MAP kinases.

Main Methods:

  • Analysis of crystallographic data for MAP kinases, specifically ERK2 and p38alpha.
  • Identification and characterization of unique substrate and small molecule binding pockets.

Related Experiment Videos

Main Results:

  • MAP kinases possess unique substrate and small molecule binding sites, including a D-motif binding site present in all MAP kinases.
  • A C-terminal binding site in p38alpha and a second substrate binding site (FXFP) in ERK2 and p38alpha were identified.
  • The FXFP binding site is exposed in active ERK2 and in MAP kinases activated by D-motif peptides.

Conclusions:

  • Novel binding sites on MAP kinases offer promising new avenues for drug development.
  • Targeting these unique sites could lead to more selective and effective therapies for various diseases.